ARTICLE | Product Development
Nkarta looks to reduce manufacturing costs with new cell therapy plant
The facility will be capable of manufacturing NK cell therapies for $2,000 per dose
July 14, 2021 4:56 PM UTC
Nkarta announced Wednesday plans to build an integrated hub comprising manufacturing and R&D facilities and company headquarters in South San Francisco.
Building a proprietary manufacturing capacity, and co-locating it with R&D, is critical to ensuring quality, reducing costs and enabling rapid iteration of manufacturing technologies, Paul Hastings, president and CEO of Nkarta Inc. (NASDAQ:NKTX), told BioCentury. ...
BCIQ Company Profiles